配对相关同源框1蛋白、癌易感性候选基因2在原发性肝癌组织中的表达及临床意义

肝癌电子杂志 ›› 2021, Vol. 8 ›› Issue (4): 21-25.

配对相关同源框1蛋白、癌易感性候选基因2在原发性肝癌组织中的表达及临床意义

李文超^1,*, 张冬², 张东霞³

1.邢台市人民医院肝病科,河北邢台 054000;
2.唐山市人民医院肝病科,河北唐山 063000;
3.邢台市人民医院急诊科,河北邢台 054000

收稿日期:2021-09-07 出版日期:2021-12-30 发布日期:2022-10-27
通讯作者: ^*李文超,E-mail：liwenchaosjz@163.com
作者简介:李文超主管护师邢台市人民医院肝病科
基金资助:
河北省2020年度医学科学研究课题计划（20201536）

Expression and clinical significance of paired related homoeobox-1 and cancer susceptibility candidate-2 in primary hepatic carcinoma

Li Wenchao^1,*, Zhang Dong², Zhang Dongxia³

1. Department of Hepatology, Xingtai People's Hospital, Xingtai 054000, Hebei, China;
2. Department of Hepatology, Tangshan People's Hospital, Tangshan 063000, Hebei, China;
3. Department of Emergency, Xingtai People's Hospital, Xingtai 054000, Hebei, China

Received:2021-09-07 Online:2021-12-30 Published:2022-10-27

摘要/Abstract

摘要： 目的：分析配对相关同源框1蛋白（paired related homoeobox-1,PRRX1）、癌易感性候选基因2（cancer susceptibility candidate-2,CASC2）在原发性肝癌组织的表达特点,探讨其与临床病理参数和预后的关系。
方法：收集2014年1月至2017年1月收治的72例经手术切除的原发性肝癌患者癌组织、癌旁组织石蜡标本。采用实时荧光定量聚合链反应（real-time fluorescence quantitative polymerization chain reaction,qRT-PCR）检测PRRX1、CASC2表达。分析PRRX1、CASC2表达与临床病理参数的关系。以随访期间患者死亡为终点事件,分析PRRX1、CASC2表达与患者预后的关系。
结果：原发性肝癌组织中PRRX1、CASC2表达均低于癌旁组织（P<0.05）。PRRX1表达与血管侵犯、肝内转移、远端转移和TNM分期有关系（P<0.05）;CASC2表达与肿瘤分化程度、TNM分期有关系（P<0.05）。Kaplan-Meier生存曲线分析结果显示,PRRX1低表达组、CASC2低表达组原发性肝癌患者3年生存率均低于PRRX1高表达组、CASC2高表达组患者（P<0.05）。多因素Cox回归分析结果显示,远端转移、PRRX1低表达、CASC2低表达与原发性肝癌患者不良预后独立相关（P<0.01）。
结论：PRRX1、CASC2在原发性肝癌组织中呈低表达。PRRX1、CASC2低表达可能与原发性肝癌发生和进展有关,可作为其预后评估的辅助指标。

关键词: 配对相关同源框1蛋白, 癌易感性候选基因2, 原发性肝癌

Abstract: Objective: To investigate the expression of paired related homoeobox-1 (PRRX1) and cancer susceptibility candidate-2 (CASC2) in primary hepatic carcinoma, and analyze their relationship with clinicopathological parameters and prognosis.
Methods: Paraffin specimens were collected from 72 patients with primary hepatic carcinoma from January 2014 to January 2017. The expressions of PRRX1 and CASC2 were detected by real-time fluorescence quantitative polymerization chain reaction (qRT-PCR), and the relationship between the expressions of PRRX1 and CASC2 and the clinicopathological parameters of primary hepatic carcinoma was analyzed. The relationship between the expression of PRRX1 and CASC2 and the prognosis of primary hepatic carcinoma patients was analyzed with death of primary hepatic carcinoma patients as the endpoint event during follow-up.
Results: The expression of PRRX1 and CASC2 in primary hepatic carcinoma tissues was lower than that in para-carcinoma tissues (P<0.05). The expression of PRRX1 was associated with vascular invasion, intrahepatic metastasis, distal metastasis and TNM stage (P<0.05). The expression of CASC2 was associated with the degree of differentiation and TNM stage (P<0.05). The results of Kaplan-Meier survival curve analysis showed that the survival rate of primary hepatic carcinoma in the low-expression group of PRRX1 and CASC2 was lower than that in the high-expression group of PRRX1 and CASC2 (P<0.05). Multivariate Cox regression analysis showed that distal metastasis, low expression of PRRX1 and CASC2 were independently correlated with poor prognosis of primary hepatic carcinoma patients (P<0.01).
Conclusions: PRRX1 and CASC2 were under expressed in primary hepatic carcinoma. Low expression of PRRX1 and CASC2 in primary hepatic carcinoma may be related to the pathogenesis and malignant progression of primary hepatic carcinoma, which can be used as an auxiliary indicator for the prognosis assessment of primary hepatic carcinoma.

Key words: Paired related homoeobox-1 proteins, Cancer susceptibility candidate-2, Primary hepatic carcinoma

李文超, 张冬, 张东霞. 配对相关同源框1蛋白、癌易感性候选基因2在原发性肝癌组织中的表达及临床意义[J]. 肝癌电子杂志, 2021, 8(4): 21-25.

Li Wenchao, Zhang Dong, Zhang Dongxia. Expression and clinical significance of paired related homoeobox-1 and cancer susceptibility candidate-2 in primary hepatic carcinoma[J]. Electronic Journal of Liver Tumor, 2021, 8(4): 21-25.

参考文献

[1] GLOBAL BURDEN OF DISEASE LIVER CANCER COLLABORATION, AKINYEMIJU T, ABERA S, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691.
[2] ALLEMANI C, MATSUDA T, DI C V, et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37, 513, 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075.
[3] FAN M, SHEN J, LIU H, et al.Downregulation of PRRX1 via the p53-dependent signaling pathway predicts poor prognosis in hepatocellular carcinoma[J]. Oncol Rep, 2017, 38(2): 1083-1090.
[4] JIN X, CAI L, WANG C, et al.CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3[J]. Cell Death Dis, 2018, 9(3): 318.
[5] YU X, ZHENG H, TSE G, et al.CASC2: An emerging tumour-suppressing long noncoding RNA in human cancers and melanoma[J]. Cell Prolif, 2018, 51(6): e12506.
[6] EDGE S B, COMPTON C C.The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-1474.
[7] PIRISI M, LEUTNER M, PINATO D J, et al.Reliability and reproducibility of the edmondso grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens[J]. Arch Pathol Lab Med, 2010, 134(12): 1818-1822.
[8] GLANTZOUNIS G K, KYROCHRISTOS I D, ZIOGAS D E, et al.Novel translational therapeutic strategy by sequencing primary liver cancer genomes[J]. Future Oncol, 2017, 13(12): 1049-1052.
[9] SAITOH M.Involvement of partial EMT in cancer progression[J]. J Biochem, 2018, 164(4): 257-264.
[10] MARCHAND B, PITARRESI J R, REICHERT M, et al.PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells[J]. Oncogene, 2019, 38(22): 4325-4339.
[11] 李宁宁, 郭振英. PRRX1在EMT及维持肿瘤干性中的研究进展[J]. 临床与实验病理学杂志, 2018, 34(4): 433-435.
[12] MARCHAND B, PITARRESI J R, REICHERT M, et al.PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells[J]. Oncogene, 2019, 38(22): 4325-4339.
[13] GUO J, FU Z, WEI J, et al.PRRX1 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer[J]. Med Oncol, 2015, 32(1): 393.
[14] 范丹, 宋文静, 张艳辉, 等. PRRX1的表达对卵巢癌血管生成拟态形成及患者预后的影响[J]. 天津医科大学学报, 2018, 24(1): 1-6.
[15] 尹东亮, 卢沛林, 尹润龙, 等. 过表达PRRX1通过p53介导的线粒体凋亡途径诱导肝癌SMMC7721细胞凋亡[J]. 中国肿瘤生物治疗杂志, 2019, 26(6): 662-668.
[16] HIRATA H, SUGIMACHI K, TAKAHASHI Y, et al.Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2015, 22(Suppl 3): S1402-S1409.
[17] RANSOHOFF J D, WEI Y, KHAVARI P A.The functions and unique features of long intergenic non-coding RNA[J]. Nat Rev Mol Cell Biol, 2018, 19(3): 143-157.
[18] SANCHEZ CALLE A, KAWAMURA Y, YAMAMOTO Y, et al.Emerging roles of long non-coding RNA in cancer[J]. Cancer Sci, 2018, 109(7): 2093-2100.
[19] WANG Y F, LIU Z K, YAO B W, et al.Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis[J]. Mol Cancer, 2017, 16(1): 123.
[20] ZHAO L, ZHANG Y J, ZHANG Y B.Long noncoding RNA CASC2 regulates hepatocellular carcinoma cell oncogenesis through miR-362-5p/Nf-κB axis[J]. J Cell Physiol, 2018, 233(10): 6661-6670.
[21] 罗剑, 王媛媛, 李爱玲, 等. 癌易感性候选基因2表达与恶性肿瘤预后相关性的系统评价[J]. 实用医学杂志, 2019, 35(1): 66-70.
[22] 辛海光, 周惠娟, 谢青. 原发性肝细胞癌的分子靶向治疗进展[J]. 肝脏, 2019, 24(7): 736-738.